Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    PT4

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 26,268Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    STIMULAN® DFO Treatment Results to be Presented at EBJIS 2025
    STIMULAN® DFO Treatment Results to be Presented at EBJIS 2025

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/results-from-big-d-foot-study-using-stimulan-when-treating-dfo-to-be-presented-at-ebjis-2025-302549594.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    FDA proposes standardized testing to detect asbestos in talc
    FDA proposes standardized testing to detect asbestos in talc

    27 Dec 2024

    // REUTERS

    https://www.reuters.com/world/us/us-fda-proposes-standardized-testing-detect-asbestos-talc-products-2024-12-26/

    REUTERS
    27 Dec 2024
    Share Share
    Tubulis Receives FDA Fast Track for TUB-040 in Ovarian Cancer
    Tubulis Receives FDA Fast Track for TUB-040 in Ovarian Cancer

    27 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240627580631/en

    BUSINESSWIRE
    27 Jun 2024
    Share Share
    Aravive Receives Third Development Milestone from 3D Medicines
    Aravive Receives Third Development Milestone from 3D Medicines

    10 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/10/2531336/30446/en/Aravive-Receives-Third-Development-Milestone-from-3D-Medicines.html

    GLOBENEWSWIRE
    10 Oct 2022
    Share Share
    Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination
    Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination

    20 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/20/2519421/0/en/Junshi-Biosciences-Receives-NMPA-Approval-of-sNDA-for-Toripalimab-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Advanced-Non-squamous-Non-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    20 Sep 2022
    Share Share
    Motto International Corp. Issues Voluntary Recall of Bull Platinum
    Motto International Corp. Issues Voluntary Recall of Bull Platinum

    19 Dec 2019

    // FDA

    https://www.pharmacompass.com/pdf/news/motto-international-corp-issues-voluntary-recall-of-bull-platinum-1576839037.pdf

    FDA
    19 Dec 2019
    Share Share